logo-loader
viewNoxopharm Ltd

Noxopharm spin-off Nyrada Inc lists on the ASX after raising $8.5 million

Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.

Noxopharm Ltd - Noxopharm spin-off Nyrada Inc lists on the ASX after raising $8.5 million
Noxopharm will remain a major shareholder in Nyrada with 2 board nominees

Noxopharm Ltd’s (ASX:NOX) spin-off company Nyrada Inc (ASX:NYR) has listed on the ASX today after raising $8.5 million from a fully subscribed initial public offer (IPO).

Nyrada is a U.S.-registered company and has listed on the ASX as a foreign entity. Accordingly, its securities will trade as CHESS Depositary Interests (CDIs).

On a fully diluted basis, Noxopharm post-listing will hold 26.9% shareholding in Nyrada. 7.1% of this shareholding is in the form of performance shares bearing the milestone of assets becoming clinic-ready.

Four drug programs

Nyrada was established in 2017 with three drug assets transferred from Noxopharm. It then acquired a fourth asset through the purchase of an external private company.

The four Nyrada drug programs are seeking the development of:

  • An oral PCSK9 inhibitor to assist in the lowering of LDL cholesterol in patients where statin therapy is inadequate;
  • A neuroprotectant to reduce secondary brain damage and long-term disability following stroke or traumatic brain injury;
  • A drug to reduce inflammation and pain in peripheral nerves associated with crush injury (eg. sciatica) and chemical injury (eg. chemotherapy); and
  • A drug to reduce chronic inflammation leading to autoimmune diseases including psoriasis and multiple sclerosis.

Quick facts: Noxopharm Ltd

Price: 0.285 AUD

ASX:NOX
Market: ASX
Market Cap: $37.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Impact of coronavirus on speciality metals 'about to bite' as China industry...

Commodity strategist and chairman of Critical Metals Plc Christopher Ecclestone gives his view on the impact he's expecting coronavirus to have on China as far as imports and exports. ''The effect so far has been limited but it's about to start to bite because with all of these speciality...

9 hours, 57 minutes ago

2 min read